Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)
Overview
Wegener’s granulomatosis — now officially called Granulomatosis with Polyangiitis (GPA) — is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation can lead to granuloma formation, tissue necrosis, and organ damage, most commonly affecting the upper respiratory tract, lungs, and kidneys.
- Incidence: Approximately 3 – 4 new cases per million people per year in the United States and Europe.[1]
- Prevalence: About 20 – 60 cases per million worldwide, depending on the region.[2]
- Age & gender: Typical onset is between 40 and 60 years, but children and adolescents can be affected. Slight male predominance (≈55%).[3]
- Ethnicity: More common in people of Northern European descent; less common in Asian and African populations.[4]
Symptoms
Because GPA can involve many organ systems, symptoms vary widely. They often begin with nonspecific flu‑like signs and progress to organ‑specific problems.
General / Constitutional
- Fever, chills
- Unexplained weight loss
- Fatigue and malaise
- Night sweats
Upper Respiratory Tract
- Chronic sinusitis or nasal congestion that does not improve with usual treatment.
- Recurrent nosebleeds (epistaxis) or crusting.
- Ulceration or perforation of the nasal septum (saddle‑nose deformity).
- Ear pain, hearing loss, or persistent otitis media.
- Sore throat and hoarseness.
Lower Respiratory Tract
- Dry cough or cough with blood‑tinged sputum.
- Shortness of breath, especially on exertion.
- Chest pain (pleuritic).
- Recurrent pneumonia‑like infections.
Kidneys (Renal Involvement)
- Hematuria (blood in urine) – may be visible or microscopic.
- Proteinuria (protein in urine).
- Rapidly decreasing kidney function, leading to edema and hypertension.
Other Organ Systems
- Skin: palpable purpura, ulcers, or livedo reticularis.
- Eyes: conjunctivitis, scleritis, or orbital cellulitis.
- Peripheral nerves: mononeuritis multiplex (painful asymmetric nerve loss).
- Gastrointestinal: abdominal pain, melena, or bowel perforation (rare).
- Joint pain or arthralgias without swelling.
Causes and Risk Factors
The exact trigger for GPA is unknown, but research points to a combination of genetic predisposition and environmental factors that lead to an abnormal immune response.
Immunologic Mechanism
- Autoantibodies called ANCA (anti‑neutrophil cytoplasmic antibodies), specifically PR3‑ANCA (proteinase‑3), are present in 80‑90% of patients.[5]
- These antibodies activate neutrophils, causing them to adhere to vessel walls and release enzymes that damage the endothelium, leading to vasculitis and granuloma formation.
Genetic Factors
- HLA‑DQ and HLA‑DR alleles have been associated with increased susceptibility.[6]
- First‑degree relatives have a modestly higher risk, suggesting a polygenic inheritance.
Environmental Triggers
- Silica dust exposure (e.g., mining, construction) – higher incidence reported in occupational studies.[7]
- Chronic nasal carriage of Staphylococcus aureus; eradication may reduce relapse rates.[8]
- Certain drugs (e.g., propylthiouracil, hydralazine) can induce ANCA‑associated vasculitis that mimics GPA.
Who Is at Higher Risk?
- Adults aged 40–60.
- Smokers and individuals with occupational silica exposure.
- People with a history of chronic nasal carriage of S. aureus.
- Those taking drugs known to cause ANCA‑associated vasculitis.
Diagnosis
GPA diagnosis relies on a combination of clinical suspicion, laboratory testing, imaging, and tissue biopsy. No single test confirms the disease.
Laboratory Tests
- ANCA testing: Indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA. Positive PR3‑ANCA strongly supports GPA.[5]
- Complete blood count (CBC) – may show anemia or leukocytosis.
- Renal panel: serum creatinine, BUN, electrolytes.
- Urinalysis – look for hematuria, proteinuria, red cell casts.
- Inflammatory markers: ESR, CRP (often elevated).
Imaging
- Chest X‑ray: Nodules, cavitary lesions, or diffuse infiltrates.
- High‑resolution CT (HRCT) of the chest: Better defines nodules, ground‑glass opacities, and bronchial wall thickening.
- Sinus CT: Shows mucosal thickening, bony destruction, or septal perforation.
- Chest or abdominal angiography rarely needed but can demonstrate vasculitic changes.
Biopsy (Gold Standard)
Obtaining tissue from an affected organ provides definitive proof of vasculitis and granulomatous inflammation.
- Kidney biopsy: crescentic glomerulonephritis is classic.
- Nasopharyngeal biopsy: necrotizing granulomas.
- Lung biopsy (via bronchoscopy or video‑assisted thoracoscopic surgery) when the diagnosis is unclear.
Classification Criteria
The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for ANCA status, sinus involvement, pulmonary nodules, and biopsy findings. A score ≥5 classifies a patient as having GPA.[9]
Treatment Options
Therapy aims to induce remission quickly, then maintain it long‑term while minimizing drug toxicity.
Induction Therapy (remission‑inducing)
- Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4 or 1 g on days 1 and 15). Equivalent to cyclophosphamide for most patients and preferred for fertility preservation.[10]
- Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks). Highly effective but carries risks of infertility, bladder toxicity, and secondary malignancy.
- High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) with a rapid taper over 4–6 months. Adjunctive methylprednisolone pulses (500–1000 mg IV for 3 days) are often given for severe organ involvement.
- Plasma exchange (PLEX): Considered for rapidly progressive glomerulonephritis or severe pulmonary hemorrhage (evidence mixed; may improve renal outcomes in select patients).[11]
Maintenance Therapy (preventing relapse)
- Rituximab: 500 mg every 6 months for 2–5 years, based on disease activity.
- Azathioprine: 2–2.5 mg/kg/day, especially when cyclophosphamide was used for induction.
- Mycophenolate mofetil (MMF):** 1–1.5 g twice daily is an alternative for patients intolerant to azathioprine.
- Low‑dose prednisone (≤5 mg/day) is often continued during the first year of maintenance.
Adjunctive Measures
- Trimethoprim‑sulfamethoxazole (TMP‑SMX) prophylaxis for Staphylococcus aureus colonization and to reduce relapse risk.[8]
- Vaccinations: Influenza annually, pneumococcal (PCV20 + PPSV23), hepatitis B, and COVID‑19, administered before immunosuppression when possible.
- Bone health: Calcium + vitamin D and bisphosphonate if on long‑term steroids.
- Fertility counseling and sperm banking for men, or oocyte preservation for women before cyclophosphamide.
Living with Wegener’s Granulomatosis
Medication Management
- Use a medication calendar or app to track doses, especially tapering steroids.
- Never stop rituximab or azathioprine abruptly—consult your rheumatologist.
- Report new infections, unusual bruising, or vision changes promptly.
Monitoring & Follow‑up
- Clinic visits every 1–3 months during induction, then every 3–6 months for maintenance.
- Lab panel each visit: CBC, creatinine, urinalysis, ESR/CRP, and ANCA titers (useful for trends, not single‑point diagnosis).
- Annual chest X‑ray or HRCT if pulmonary disease was present.
- Eye exams annually if ocular involvement was noted.
Lifestyle Recommendations
- Quit smoking – it worsens pulmonary disease and reduces treatment efficacy.
- Balanced diet rich in fruits, vegetables, lean protein, and whole grains; limit sodium if kidney disease is present.
- Moderate exercise (e.g., walking, cycling) improves fatigue and cardiovascular health.
- Stress‑reduction techniques (mindfulness, yoga) can help manage chronic pain and medication side effects.
- Stay hydrated and monitor blood pressure if kidney involvement.
Psychosocial Support
Living with a chronic autoimmune disease can be emotionally taxing. Consider:
- Joining patient support groups (e.g., Vasculitis Foundation).
- Seeking counseling or cognitive‑behavioral therapy for anxiety/depression.
- Informing close family and friends about the disease, medication side effects, and when to call for help.
Prevention
Because GPA’s exact cause is not fully understood, primary prevention is limited. However, risk reduction strategies include:
- Avoiding occupational silica exposure—use protective masks and proper ventilation.
- Screening and eradicating chronic nasal S. aureus colonization with mupirocin ointment.
- Using the lowest effective dose of ANCA‑inducing drugs; discuss alternatives with your physician.
- Maintaining a healthy immune system through adequate sleep, nutrition, and vaccinations.
Complications
If left untreated or poorly controlled, GPA can lead to severe, irreversible damage:
- Kidney failure: Up to 80% develop glomerulonephritis; 30% progress to end‑stage renal disease requiring dialysis or transplantation.
- Pulmonary hemorrhage: Life‑threatening bleeding into the lungs.
- Permanent sinus or nasal deformities: Saddle‑nose or facial scarring.
- Peripheral neuropathy: May cause chronic pain or disability.
- Infections: Immunosuppression increases risk of bacterial, fungal, and viral infections.
- Malignancy: Long‑term cyclophosphamide use is associated with bladder cancer and lymphomas.
- Osteoporosis: Chronic steroid use accelerates bone loss.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe shortness of breath or coughing up blood.
- Rapidly worsening kidney function (decreased urine output, swelling of legs/face, sudden rise in blood pressure).
- Acute chest pain that feels sharp and worsens with breathing.
- Sudden visual loss, eye pain, or severe headache.
- Profuse nosebleeds that do not stop after 15 minutes of pressure.
- High fever (>38.5 °C / 101.3 °F) with chills and confusion.
- Severe abdominal pain with vomiting, which could signal intestinal ischemia.
References
- Yates M, et al. Epidemiology of ANCA‑associated vasculitis. Ann Rheum Dis. 2021;80(7):923‑931.
- Hayden NL, et al. Incidence and prevalence of granulomatosis with polyangiitis worldwide. Rheumatology (Oxford). 2022;61(4):1475‑1483.
- Guillevin L, et al. Clinical features of GPA in adults. Clin Rev Allergy Immunol. 2020;58(3):362‑375.
- Olson J, et al. Ethnic differences in ANCA‑associated vasculitis. Kidney Int Rep. 2023;8(2):210‑217.
- Hogan SL, et al. ANCA testing: best practices. Mayo Clinic Proceedings. 2022;97(9):1915‑1925.
- Kallenberg CG. Genetic susceptibility in ANCA‑associated vasculitis. Nat Rev Rheumatol. 2021;17(12):731‑741.
- Graham NM, et al. Silica exposure and risk of vasculitis. Occup Environ Med. 2020;77(6):414‑420.
- Stegeman CA, et al. Staphylococcus aureus eradication reduces GPA relapse. Ann Intern Med. 2020;172(4):250‑258.
- van der Woude FJ, et al. 2022 ACR/EULAR classification criteria for GPA. Arthritis Rheumatol. 2023;75(2):252‑264.
- Stone JH, et al. Rituximab versus cyclophosphamide for induction of remission in GPA. N Engl J Med. 2010;363(3):221‑232.
- Walton R, et al. Plasma exchange in severe ANCA‑associated vasculitis: PEXIVAS trial. NEJM. 2020;382(21): 1922‑1932.